Cell lines

RSSL announces launch of new innovation hub to support biotech companies

28-Feb-2024 By Liza Laws

RSSL, a leading pharmaceutical contract research organisation, has unveiled plans for its newest venture, the Innovation Hub.

Webinar: Innovations in drug delivery - tune in and join our excellent panel

27-Feb-2024 By Liza Laws

As the landscape of healthcare continues to evolve, so too does the field of drug delivery.

Cytomos unveils new brand and revamped website

19-Dec-2023 By Isabel Cameron

Biotech company Cytomos has announced the creation of its newly named AuraCyt cell analysis technology brand and the launch of its improved website.

Women in Science: An instant passion for science and thriving in a male-dominated industry

13-Dec-2023 By Liza Laws

Lisa Sellers is the CEO of Vector Laboratories, and she is passionate about staying ahead of the pharma trends.

Women in Science: Cynthia Pussinen, CEO of Sernova on how her career was 'written in the stars'

15-Nov-2023 By Liza Laws

Cynthia Pussinen knew she wanted to work in STEM fields by the time she was a teenager, she received a full scholarship to study nuclear engineering but after two years changed to chemistry for her major.

Angle launches PD-L1 test to support cancer therapy studies

13-Nov-2023 By Isabel Cameron

Angle, a liquid biopsy company with circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology, has launched its Portrait PD-L1 test for the evaluation of PD-L1 protein expression on CTCs.

Galapagos enlists Landmark Bio to manufacture CAR-T therapies in Boston

07-Nov-2023 By Jonathan Smith

The Belgian biotech company Galapagos will work with Landmark Bio to deliver CAR-T cell therapies to patients more quickly than with traditional manufacturing methods.

Synthego and bit.bio expand partnership to build cell engineering platform

29-Aug-2023 By Isabel Cameron

Synthego, a leading provider of industrialized genome editing solutions, and bit.bio, the company coding human cells for novel cures, have expanded their partnership to build a platform centered on the implementation of synthetic circuitry in cells for...

AGC Biologics completes expansion at Milan cell and gene therapy site

10-Aug-2023 By Isabel Cameron

AGC Biologics, a global contract development and manufacturing organization (CDMO), has completed the expansion of its manufacturing space at its Milan Cell and Gene Center of Excellence production site.

Cytiva and Pall Life Sciences complete integration: ‘Uniting gives us the focus, expertise and talent to help our customers discover, develop and deliver the next generations of novel therapeutics’

02-May-2023 By Rachel Arthur

Cytiva and the life sciences business of Pall Corporation are now united as one business under the Cytiva brand, with the completion of the integration announced this morning. Emmanuel Ligner, Danaher Group Executive, President and CEO of Cytiva, tells...

Ginkgo touts gene therapy one-stop shop capabilities following acquisition

11-Apr-2023 By Ben Hargreaves

Ginkgo acquires StrideBio's adeno-associated virus (AAV) capsid discovery and engineering platform assets and as well as gaining ownership of a preclinical asset.

Avid Bioservices unveils mammalian cell facilities expansion

06-Apr-2023 By Rachel Arthur

Avid Bioservices, a dedicated biologics CDMO in the US, has completed two expansions within the company’s mammalian cell facilities

Sartorius to acquire Polyplus

03-Apr-2023 By Rachel Arthur

Life science group Sartorius will acquire French company Polyplus for around €2.4bn ($2.6bn).

US government announces ambitions for biomanufacturing

28-Mar-2023 By Ben Hargreaves

The White House releases a report detailing how it will harness biotechnology and biomanufacturing to address numerous societal challenges, including human health.

PackGene breaks ground on biomanufacturing and process development facility in Houston

28-Feb-2023 By Rachel Arthur

PackGene Biotech, an adeno-associated virus (AAV) vector contract research organization (CRO) and contract development and manufacturing organization (CDMO), is expanding its US services with a new cGMP biomanufacturing and processing facility in Houston....

New Lonza facility set to support US biotechs in managing the path to commercialization of novel therapies

14-Feb-2023 By Jane Byrne

Switzerland headquartered Lonza said it is expanding its early development services (EDS) to North America, opening a new laboratory in Cambridge, Massachusetts (US).

CBM looks to boost viral vector manufacturing capabilities in cell line deal

19-Jan-2023 By Jane Byrne

The unprecedented rise in approvals for new cell and gene therapies, and the increasing industry need for cell lines to support the production of therapeutics, has spurred US CDMO, the Center for Breakthrough Medicines (CBM), to act

UK ATMP clinical research picture remains positive despite challenging global environment

17-Jan-2023 By Jane Byrne

In 2022, the UK continued to have a signficant footprint in ATMP clinical research, with total ongoing trials increasing from 168 in 2021 to 178 in 2022, according to a new report.

Lonza to support manufacturing of bispecific antibody drug candidate

09-Jan-2023 By Jane Byrne

Lonza and Context Therapeutics are collaborating on the manufacture of a bispecific antibody-based therapy.

BioNTech acquires GMP manufacturing site in Singapore

14-Nov-2022 By Rachel Arthur

BioNTech will create an mRNA facility in Singapore through the acquisition of a Novartis site: which will become its Regional Headquarters and production center for the Asia Pacific region.

VGXI opens new HQ and manufacturing facility in Texas

24-Oct-2022 By Rachel Arthur

CDMO VGXI has officially opened its new headquarters and manufacturing facility in Conroe, Texas.

Andelyn Biosciences opens GMP manufacturing facility

20-Oct-2022 By Rachel Arthur

US gene therapy CDMO, Andelyn Biosciences, has opened a new GMP clinical and commercial manufacturing facility to support cell and gene therapy (CGT) development and manufacturing.

Cytiva acquires CEVEC Pharmaceuticals, strengthening cell line development

06-Oct-2022 By Rachel Arthur

Cytiva has acquired CEVEC Pharmaceuticals, a German provider of cell line development and viral vector manufacturing technologies.

RoosterBio and MBL Beijing Biotech team up to accelerate advanced therapy manufacturing in China

01-Sep-2022 By Rachel Arthur

RoosterBio has entered into an exclusive distributor partnership with MBL Beijing Biotech: with RoosterBio’s expansion media, exosome collection media, bioreactor media and genetic engineering media to be sold and distributed by MBL Beijing and thus becoming...

Applied StemCell expands manufacturing facility to support cell and gene therapies

30-Aug-2022 By Rachel Arthur

Applied StemCell is expanding its cGMP facility to increase its cell banking and cell product manufacturing capacity.

Resilience and Mayo Clinic create biomanufacturing partnership for rare and complex conditions

16-Aug-2022 By Rachel Arthur

Biomanufacturing company National Resilience has announced a strategic collaboration with Mayo Clinic in biomanufacturing to deliver novel biotherapeutics for rare and complex conditions.

Sartorius to acquire Albumedix for $502m

09-Aug-2022 By Rachel Arthur

Life science group Sartorius will acquire UK recombinant albumin-based solution company Albumedix.

RoslinCT and Lykan Bioscience combine to create advanced cell therapy CDMO

04-Aug-2022 By Rachel Arthur

Edinburgh CDMO RoslinCT and Massachusetts CDMO Lykan Bioscience will combine to create a global advanced therapies CDMO: offering significantly expanded manufacturing capacity.

Thermo Fisher Scientific expands New York cell culture media manufacturing site

04-Aug-2022 By Rachel Arthur

A $76m investment in the facility in Grand Island, New York, will increase capacity to produce raw materials used in manufacture of vaccines and biologic therapies.

Samsung Biologics on track to open ‘super plant’ in October

28-Jul-2022 By Rachel Arthur

Construction of Samsung Biologics’ Plant 4 is on schedule with operations set to start in October, the company confirmed in its Q2 results this morning.

WuXi Biologics to build CRDMO center in Singapore

21-Jul-2022 By Rachel Arthur

CDMO WuXi Biologics will invest $1.4bn in a 10 year investment plan to expand its research, development, and large-scale drug substance and drug product manufacturing capacity and capabilities in Singapore.

Vertex to acquire ViaCyte, targeting type 1 diabetes

12-Jul-2022 By Rachel Arthur

Vertex Pharmaceuticals will acquire ViaCyte, a privately held biotech focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes (T1D), for $320m.

‘A new Alzheimer’s treatment is on the horizon’: Cell therapy reverses dementia-like syndrome in dogs

27-Jun-2022 By Rachel Arthur

Australian biotech Skin2Neuron’s new form of cell therapy reversed a dementia-like syndrome in dogs, according to results of a veterinary trial.

New collaboration to accelerate advancements in gene therapies for dementia

20-Jun-2022 By Rachel Arthur

The Cell and Gene Therapy Catapult (CGT Catapult) and the UK Dementia Research Institute (UK DRI) have announced a collaboration to accelerate clinical development of adeno-associated virus (AAV) based gene therapies for dementia.

bio 2022

ten23 adds manufacturing building in rapid build out

14-Jun-2022 By Ben Hargreaves

The newly launched CDMO plans to set up two new manufacturing lines, after expanding into a 5,000-square-meter manufacturing facility.

Charles River and ASC Therapeutics expand gene therapy manufacturing agreement

13-Jun-2022 By Rachel Arthur

Charles River Laboratories International and ASC Therapeutics have announced plans to manufacture ASC618, a second-generation gene therapy for hemophilia A.

Evotec expands cell therapy manufacturing with acquisition

31-May-2022 By Ben Hargreaves

Evotec agrees to acquire Rigenerand, which adds a manufacturing facility capable of producing cell therapies to its infrastructure in Italy.

AGC Biologics adds new viral vector suspension capabilities at US cell & gene facility

19-May-2022 By Rachel Arthur

AGC Biologics will add viral vector suspension technology and capacity for the development and manufacturing of gene therapies at its commercial-grade campus in Longmont, Colorado.

Swiss biotech R&D investments reach record high

09-May-2022 By Rachel Arthur

Capital investments in Swiss biotech companies reached CHF 3.33bn ($3.53bn) in 2021; while R&D investments increased to a record-high CHF 2.56bn ($2.71bn).

Matica Bio opens new Texas cell and gene therapy facility

06-May-2022 By Rachel Arthur

CDMO Matica Bio has opened a new 45,000-square-foot facility dedicated to the production of viral vectors and cell-based products used in cell and gene therapies, vaccines, oncolytic therapies and other genetic medicines.

ExcellGene and Cytena team up to optimize workflows for mAb and therapeutic protein manufacturing

05-May-2022 By Jane Byrne

ExcellGene SA, a Swiss biologics focused CDMO, has established a collaboration agreement with German biological cell instrument developer, Cytena.

Catalent acquires New Jersey cell therapy development and manufacturing facility

25-Apr-2022 By Rachel Arthur

Catalent has acquired a commercial-scale cell therapy manufacturing facility in Princeton, New Jersey, from Erytech Pharma for $44.5m.

CytoImmune Therapeutics opens clinical cell manufacturing facility in Puerto Rico

28-Mar-2022 By Rachel Arthur

CytoImmune Therapeutics, a clinical-stage immunotherapy company developing a novel class of engineered natural killer (NK) cell-based cancer therapies, has announced the opening of its clinical cell manufacturing facility in Toa Baja, Puerto Rico.

WHO establishes global biomanufacturing training hub in Korea

25-Feb-2022 By Rachel Arthur

A global biomanufacturing training hub will be established in Korea to serve low- and middle-income countries wishing to produce biologicals such as vaccines, insulin, monoclonal antibodies and cancer treatments.

Wheeler Bio looks to solve tech transfer challenges, raises $14m in seed funding

11-Jan-2022 By Jane Byrne

Wheeler Bio, a newly established company aiming accelerate the translation of therapeutic innovation into clinical impact, recently closed a US$14m seed financing round.

Tech transfer box ticked in Catalent and BrainStorm cell therapy alliance

09-Dec-2021 By Jane Byrne

Catalent is reporting that the technology transfer for the manufacture of BrainStorm Cell Therapeutics’ autologous cellular therapy at its facility in Houston, Texas has been finalized.

Operations begin at new Genezen lentiviral and retroviral vector lab in Indianapolis

06-Dec-2021 By Jane Byrne

Genezen, a cell and gene therapy focused CDMO, has just opened a new process development and analytical lab, a build that represents the first phase of a 75,000+ square foot cGMP-compliant lentiviral and retroviral vector production facility in Indianapolis.

Emulate enhances tech aimed at supporting disease research and drug development

22-Nov-2021 By Jane Byrne

Emulate, Inc recently launched the Zoë-CM2 Culture Module, a second-generation Zoë instrument core to its ‘Organ-on-a-Chip’ based Human Emulation System.

CJ Cheiljedang set to acquire Batavia Biosciences for $226m

08-Nov-2021 By Jane Byrne

CJ Cheiljedang, a subsidiary of South Korea's food and entertainment giant, CJ Group, is about to enter the biopharma CDMO business.

Sphere Fluidics closes $40m funding round

05-Nov-2021 By Jane Byrne

Sphere Fluidics, a UK company that has developed and is commercializing single cell analysis systems underpinned by its picodroplet technology, has just closed a US$40m investment round.